Minapharm Pharmaceuticals

What Minapharm Pharmaceuticals does

Minapharm Pharmaceuticals is an Egyptian-domiciled, publicly traded pharmaceutical and biopharmaceutical group (Egyptian Exchange: MIPH), founded in the early 1950s and re-established in 1992, headquartered in Cairo with operating subsidiaries in Berlin. The company develops, manufactures, and commercializes over 150 life-saving products spanning small molecules, biosimilars, recombinant proteins, monoclonal antibodies, viral vectors, and cell and gene therapies. It is the only gene-to-market biopharmaceutical company in Africa and the Middle East, anchored on proprietary technology platforms sourced primarily through its wholly-owned Berlin subsidiary ProBioGen AG (acquired 2010), which provides CHO and yeast (Hansenula polymorpha) cell line engineering, glycoengineering, single-use bioreactor (250ml-2000L), continuous chromatography, transposase, AGE1.CR.ReX avian designer cell line, and viral vector technologies. The group operates three subsidiaries: MiGenTra Egypt (biopharmaceutical manufacturing in Cairo), ProBioGen AG (Berlin-based CDMO serving global biotech), and MiGenTra GmbH (cell and gene therapy hub with 40,000L fermenter capacity at a 15,000m2 EMA-compliant facility).

The company operates four revenue streams: (1) pharmaceutical and biopharmaceutical product manufacturing and sales across 15+ MEA countries through direct sales and partner networks; (2) contract development and manufacturing organization (CDMO) services via ProBioGen AG; (3) technology licensing of proprietary platforms; and (4) in-licensing and out-licensing of products with multinational partners. Key commercial relationships span flagship-tier agreements with Bayer (women's health localization, Nov 2025), Sanofi (Clexane localization, Dec 2023), LEO Pharma (three-decade dermatology partnership expanded in 2023), Alvotech/Bioventure (biosimilar commercialization in 19 MEA countries), IAVI (vaccine development partnership, Oct 2025), RDIF (Sputnik V manufacture, 2021), and Cheerland Biotechnology (MEA-Asia collaboration). The group produces 7 self-developed approved biologics including Extrauma DNA, Thrombexx, Gonapure (recombinant FSH), Reiferon Retard, Bonosome (teriparatide biosimilar), Adessia (adalimumab biosimilar in Phase 1), and Neureight (recombinant FVIII), with manufacturing and product capabilities verified under cGMP, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, EMA, and WHO guidelines.

Minapharm is majority-owned through holding company Triquera B.V., into which Africa-focused private equity firm Admaius Capital Partners invested in July 2025, with additional growth funding from the African Development Bank (April 2025) and the European Bank for Reconstruction and Development (January 2026). Recent capital deployment includes acquisition of global Praxilene rights from Merck (January 2026), establishment of a Sub-Saharan Africa office and Minapharm Consumer Health business segment in 2025, and a partnership with the American University in Cairo (January 2026) to establish the first African Academy for Biotechnology. The company employs 2,000+ staff across six facilities spanning Cairo, 10th of Ramadan City, and Berlin.

Name

Minapharm Pharmaceuticals

Legal name

MINAPHARM Pharmaceuticals

Website

https://minapharm.com

Company type

Public

Founded year

1950

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Minapharm Pharmaceuticals is a publicly-traded Egyptian biopharmaceutical group that develops, manufactures, and commercializes 150+ products spanning small molecules, biosimilars, and cell and gene therapies across Africa and the Middle East, operating six manufacturing facilities in Cairo and Berlin through ProBioGen AG CDMO services and proprietary cell-line platforms.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

Keywords

• Biopharmaceutical manufacturing
• Recombinant protein production
• Biosimilar development
• CDMO services
• Cell line engineering

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

1. Pharmaceutical Products Manufacturing & Sales: Minapharm develops, manufactures and commercializes over 150 life-saving and life-enhancing products ranging from small molecules to complex bioengineered proteins. Products are sold through direct sales and distribution networks across Middle East, Africa, and global markets.
2. CDMO Services: Contract development and manufacturing organization services through ProBioGen AG providing cell line engineering, process development, and GMP manufacturing to global biotech industry.
3. Technology Licensing: Licensing of proprietary technologies to global biotech industry, including protein production technologies, viral vector technologies, and cell therapy expertise.
4. In-licensing & Out-licensing: In-licensing of products to enhance portfolio and pipeline; out-licensing of established biopharmaceutical and pharmaceutical portfolio to emerging countries.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Minapharm develops, manufactures, and commercializes over 150 pharmaceutical and biopharmaceutical products spanning small molecules to complex bioengineered proteins, biosimilars, vaccines, and cell & gene therapies. Through its Berlin subsidiary ProBioGen AG, it also provides CDMO services and licenses proprietary cell line, glycoengineering, and viral vector technologies to the global biotech industry.

Product overview

Minapharm Pharmaceuticals is a biopharmaceutical company offering a broad portfolio of over 150 life-saving and life-enhancing products ranging from small molecules to complex bioengineered proteins. The company's products are organized into two main categories: Biopharmaceutical Products (including recombinant proteins, monoclonal antibodies, biosimilars, and cell & gene therapies) and Pharmaceutical Products (small molecules with advanced galenic formulations). Key biopharmaceutical products include Extrauma DNA/Thrombexx (topically applied recombinant proteins for thrombosis), Gonapure (recombinant FSH for infertility), Reiferon Retard (PEGylated interferon for hepatitis C), Bonosome (teriparatide biosimilar for osteoporosis), and Adessia (adalimumab biosimilar in development). The company operates through three main subsidiaries: MiGenTra Egypt (biopharmaceutical manufacturing), ProBioGen AG (Berlin-based CDMO), and MiGenTra GmbH (cell and gene therapy). Minapharm's portfolio spans therapeutic areas including cardiology, gastroenterology, ophthalmology, orthopedics, uro-gynecology, respiratory, dermatology, and pediatrics.

Differentiator

Problem solved

Functional benefit

Brands

• MiGenTra: Healthcare transforming medicines company for development and commercialization of biosimilars, CGTs and vaccines for MEA region.
• ProBioGen AG
• MiGenTra Egypt

Products and services

• Extrauma DNA Topically applied recombinant protein brand containing 280 IU Recombinant Hirudin for local treatment; positioned as the world's first topically applied recombinant protein.
• Thrombexx Topically applied recombinant protein brand (available in cream and gel formulations) for treatment of serious thrombotic complications.
• Gonapure Recombinant human FSH (Follicle Stimulating Hormone), available in 75 and 150 IU presentations, for infertility treatment. First mammalian-derived product launched by Minapharm.
• Reiferon Retard PEGylated Interferon-alpha 2a product for hepatitis C treatment; first PEGylated Interferon launched by Minapharm.
• Bonosome Recombinant Teriparatide biosimilar for osteoporosis treatment; first African biologic to complete clinical trials in Germany.
• Adessia Adalimumab biosimilar in development for autoimmune diseases; approved for Phase 1 clinical trials in Germany by the Paul-Ehrlich Institute.
• Neureight Recombinant full-length factor VIII (FVIII) produced by fed-batch process in disposable bioreactors for hemophilia A treatment.
• Angiofox Biphasic capsules for cardiovascular treatment.
• Artelac Eye drops for ophthalmology treatment.
• Betolvex Iron deficiency treatment in ampoules/pre-filled syringes.
• Fucidin / Fucicort Dermatology products for skin infections, psoriasis, and atopic dermatitis, manufactured and commercialized under exclusive license from LEO Pharma.
• Biogaia Protectis Probiotic baby drops for gut health, licensed from BioGaia and sold in Egypt under the BioGaia brand.
• Clexane (localized) Low molecular weight heparin (enoxaparin sodium) for thrombosis prophylaxis and treatment, manufactured in Egypt under an exclusive manufacturing and supply agreement with Sanofi.
• ProBioGen CDMO Services Contract development and manufacturing (CDMO) services through Berlin-based ProBioGen AG, including cell line engineering, process development, candidate characterization, bioassays, and GMP manufacturing for the global biotech industry.
• Technology Licensing Licensing of proprietary biopharmaceutical technologies (cell line development, glycoengineering, viral vector technologies, TetherexX System) to global biotech companies for protein production, vaccines, and cell therapy.

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

13 partnerships are on record, tiered flagship, core and minor.

• ProBioGen AGflagshipTechnology or Integration · 27 May 2026ProBioGen launched AGE1.CR.ReX, an avian designer cell line for stable, high-titer production of recombinant MVA and other poxviruses. The technology is being applied in ProBioGen and Minapharm's joint initiative to develop an African Bundibugyo Ebola virus vaccine, positioned as a rapid response platform for epidemic preparedness.
• American University in Cairo (AUC)coreStrategic or Co-development Partner · 5 January 2026Partnership to establish the first African academy for biotechnology. Focus on bridging gap between academic training and practical industry competencies through joint workshops, collaborative research, and hands-on training at Minapharm's industrial facilities.
• Bayer InternationalflagshipStrategic or Co-development Partner · 15 November 2025Strategic cooperation agreement signed between Minapharm and Bayer to localize pharmaceutical manufacturing and introduce advanced technologies in Egypt. Aims to enhance Egypt's national manufacturing capabilities, support local healthcare initiatives, and reinforce Egypt's role as a regional pharmaceutical hub. Focus on women's health and family planning products.
• IAVIflagshipStrategic or Co-development Partner · 10 October 2025Strategic partnership between IAVI, Minapharm, and ProBioGen to advance end-to-end development and manufacturing of priority vaccines and biologics in Africa. Focus on clinical development, manufacturing, commercialization, and access.
• Cheerland BiotechnologycoreStrategic or Co-development Partner · 21 December 2023MoU signed between Minapharm and Cheerland Biotechnology (CLB), a global biologics CDMO based in China, to jointly pursue potential business opportunities in MEA region and Asia.
• SanofiflagshipStrategic or Co-development Partner · 5 December 2023Exclusive Manufacturing and Supply Agreement for localization of the full range of Clexane (enoxaparin sodium), Sanofi's flagship market leader product, in Egypt. Boosts Egypt's national localization strategy of biopharmaceutical manufacturing.
• SaudiVaxcoreStrategic or Co-development Partner · 26 September 2023MoU signed for strategic partnership in Saudi Arabia and Gulf Cooperation Countries. Leverages Minapharm and MiGenTra's development and manufacturing technologies with SaudiVax's industrial capabilities and commercial reach in the region.
• LEO PharmacoreChannel Partner/ Reseller/ Distributor · 21 May 2023Exclusive agreement expanding longstanding strategic manufacturing partnership of three decades. Covers Fucidin and Fucicort brands with dominant market shares. New agreement adds commercialization of full portfolio of innovative dermatologic therapeutics for psoriasis and atopic dermatitis.
• BioventurecoreChannel Partner/ Reseller/ Distributor · 28 November 2022Exclusive license agreement for commercialization of multiple biosimilar candidates developed and manufactured by Alvotech in Egypt and eighteen additional countries in Africa and the Middle East.
• BioGaiaminorChannel Partner/ Reseller/ Distributor · 9 May 2021Exclusive rights to sell BioGaia Protectis drops in Egypt under the BioGaia brand. Product launch planned for Q4 2021.
• Russian Direct Investment Fund (RDIF)flagshipStrategic or Co-development Partner · 22 April 2021Agreement to produce over 40 million doses per year of Sputnik V COVID-19 vaccine in Egypt. Minapharm, its Berlin subsidiary ProBioGen AG, and RDIF partnered for this manufacturing initiative.
• ProBioGen AGflagshipTechnology or Integration · 19 April 2007Development and co-promotion agreements between ProBioGen and Minapharm to develop two therapeutic proteins. ProBioGen was acquired by Minapharm in 2010.
• Rhein-Biotech (now Dynavax Europe)flagshipStrategic or Co-development Partner · 1 January 2001Original joint-venture partner for establishment of MiGenTra Egypt, the first biotech firm in Egypt, Africa, and the Middle East. Focused on process development and drug substance manufacturing of therapeutic recombinant proteins.

Scale indicators11 records

Recent moves13 records

Expansion highlights9 records

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered specialty pharmaceutical company with a major presence in MEA and the US, operating branded generics, injectables, and increasingly biologics. Directly comparable as a MEA-anchored pharma platform expanding into specialty/biologics manufacturing and out-licensing across the same geographies.
• Eva Pharma: Leading Egyptian pharmaceutical manufacturer offering branded generics, biosimilars, and APIs across MEA. Closely comparable in geographic base, product breadth (small molecules to biologics), and the strategic intent to localize advanced manufacturing in Egypt.
• EIPICO: Egyptian pharmaceutical company producing a wide range of generic and specialty medicines, including sterile injectables and biosimilars. Comparable as a domestic Egyptian manufacturer expanding into biologics and regional export markets.
• Mabxience: Global biosimilars CDMO and developer, part of the Insud Pharma group, with facilities in Spain and Argentina. Directly comparable as a CDMO-led biosimilar platform using mammalian cell culture to supply emerging and regulated markets.

Broad incumbents

• Aspen Pharmacare: Largest African pharmaceutical manufacturer, headquartered in South Africa, with diversified branded generics, specialty, and sterile manufacturing capacity. Comparable as an Africa-headquartered platform that has scaled regional pharma manufacturing into global markets.
• Samsung Biologics: World-leading biologics CDMO with very large-scale mammalian cell culture capacity. Comparable as a CDMO peer to ProBioGen AG, providing process development, GMP manufacturing, and technology services to global biotech and pharma clients.
• Cipla: Indian-headquartered global pharmaceutical company with a strong African footprint (third-largest pharma presence in Africa) and a growing biosimilars and complex generics portfolio. Comparable in its MEA commercial reach and emerging-market pharma + biologics strategy.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing generics and biologics across the Middle East. Comparable as a MEA-anchored pharma manufacturer pursuing biosimilars and regional self-sufficiency in drug supply.
• Spimaco: Saudi Arabian pharmaceutical manufacturer with branded generics, sterile injectables, and biologics ambitions. Comparable as a MEA-headquartered manufacturer pursuing regional pharma localization and in-licensing partnerships with multinational innovators.

Emerging players

• SaudiVax: Saudi Arabian biopharmaceutical CDMO and vaccines developer. Already a Minapharm partner (2023 MoU) and a directly comparable emerging regional CDMO focused on localizing biologics and vaccine manufacturing in the Gulf.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=X4IGjCYRiz4
• LinkedInlinkedin.com/company/minapharm-pharmaceuticals

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minapharm Pharmaceuticals